- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02668315
Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant
A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Investigators are proposing a phase I-II, Canadian multi-center, open-label study of UM171 ex vivo expanded CB transplant in 25 patients who need an allogeneic hematopoietic stem cell transplantation (HSCT) but lack a Human Leucocyte Antigen (HLA) matched donor.
Investigators key primary and secondary objectives include:
- To establish the feasibility of expanding cord blood units for allogeneic cord blood transplantation.
- To establish the safety and identify unexpected toxicities associated with the transplantation of cord blood cells expanded with UM171/fed-batch culture system.
- To measure kinetics of neutrophil and platelet recovery.
- To determine minimal cord blood unit cell dose (Total Nucleated Cell (TNC)/CD34+ cells) that when expanded achieves prompt engraftment as a single cord transplant.
Methodology:
Patients with a hematologic malignancy and an indication for allogeneic HSCT who lack a matched unrelated donor will receive a myeloablative or submyeloablative conditioning regimen followed by infusion of UM171 expanded CB graft. Accrual is expected to last 18 months and patients will be followed for 3 years.
Expected benefits:
Investigators expect that expansion with UM171/fed-batch will be safe and lead to both rapid and sustained engraftment. This will likely decrease the high early morbidity/mortality of CB HSCT and improve access to transplant, especially ethnic minorities. In addition, if low cell dose is solved, patients will benefit from CB's lower risk of chronic (graft versus host disease) GVHD, a major cause of morbidity.
.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H1T2M4
- Hôpital Maisonneuve-Rosemont
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion
- 3-64 years old (Pediatric patients will become eligible only after 5 adult patients have been enrolled in the study and received the UM171 expanded product).
- Weight ≥ 12kg
- Underlying hematologic malignancy excluding primary myelofibrosis requiring an unrelated donor allogeneic HSC transplant (as defined by the transplant center) but patient lacks an 8/8 HLA identical donor or disease requires an urgent transplant and cannot wait the required time to identify an unrelated donor.
Availability of at least 3 cord bloods with HLA match ≥ 4/6 and ≥4/8 and meeting the following requirements:
- CB to be expanded: CD34+ cell count 1.0-4.9 x 10E5/kg for cohort 1, 0.5-4.9 x 10E5/kg for cohort 2, and 0.25-4.9 x 10E5/kg for cohort 3; nucleated cell count ≥ 2.0 x 10E7/kg for cohort 1, ≥ 1.5 x 10E7/kg for cohort 2, and ≥ 1.25 x 10E7/kg for cohort 3.
- Non expanded cord: TNC count ≥ 2.0 x 10E7/kg with CD34 min of 1 x 10E5/kg or minimum of 1.5 x 10E7 TNC/kg with 1.8 x 10E5 CD34+ cells/kg.
- Back up cord: TNC count ≥ 1.5 x 10E7/kg with CD34 min of 1 x 10E5/kg
- Left ventricular ejection fraction > 40%.
- Karnofsky score ≥ 70%
- Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and diffusing capacity corrected for hemoglobin (DLCOc) ≥ 50% of predicted
- Bilirubin < 2 x upper limit of normal (ULN) unless felt to be related to Gilbert's disease or hemolysis; AST (aspartate aminotransferase) and ALT (alanine aminotransférase) ≤ 2.5 x ULN; alkaline phosphatase ≤ 5 x ULN.
- Measured or estimated creatinine clearance ≥ 60 ml/min/1.73m2.
Exclusion
- Myeloablative transplant within 24 months.
- Uncontrolled infection.
- Presence of a malignancy other than the one for which the UCB transplant is being performed and the expected survival related to the malignancy is estimated to be less than 75% at 5 years.
- HIV positivity.
- Hepatitis B or C infection with measurable viral load.
- Liver cirrhosis.
- Availability of a cord with ≥ 5 x 105/kg CD34+ cells.
- Pregnancy, breastfeeding or unwillingness to use appropriate contraception.
- Participation in a trial with an investigational agent within 30 days prior to entry in the study.
- Patient unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and tests.
- Any abnormal condition or laboratory result that is considered by the principal investigator capable of altering patient condition or study outcome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 1.0-4.9
x 10E5/kg and TNC superior or equal to 2.0 x 10E7/kg
|
Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
|
Experimental: Cohort 2
Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.5-4.9
x 10E5/kg and TNC superior or equal to 1.5 x 10E7/kg
|
Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
|
Experimental: Cohort 3
Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.25-4.9
x 10E5/kg and TNC superior or equal to 1.25 x 10E7/kg
|
Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monitoring adverse events, toxicities and medical evolution
Time Frame: up to 36 months post transplant
|
To identify unexpected toxicities associated with transplantation using cord blood cells expanded with UM171/fed-batch culture system by means of history, physical examination and laboratory evaluation.
All adverse events will be evaluated for duration, intensity, and causal relationship with the study medication and followed to the end of the study or until resolution.
|
up to 36 months post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of cord blood expansion using UM171 (transplant success)
Time Frame: 18 months
|
The feasibility of expanding cord blood units for allogeneic cord blood transplantation in adults will be evaluated by determining the percentage of selected grafts that will be successfully expanded in the absence of technical hurdles such as contamination or unexpected technical failure, and that will meet release criteria and be successfully infused in patients.
|
18 months
|
Kinetics of hematopoietic recovery
Time Frame: 42 days post transplant
|
Time to neutrophil engraftment is defined as the first day of attainment of an absolute neutrophil count (ANC) ≥ 0.5 x 109/L for 3 consecutive days as per Center for International Blood and Marrow Transplant Research (CIBMTR) standards. Platelet engraftment is defined as the first day of a sustained platelet count ≥ 20 x 109/L with no platelet transfusion in the preceding 7 days as per CIBMTR standards. |
42 days post transplant
|
Minimal cord blood cell dose that when expanded achieves prompt engraftment
Time Frame: up to 12 months
|
The minimal cord blood unit cell dose (TNC/CD34+) that, once expanded, achieves prompt engraftment as a single cord transplant will be defined as the lower cord blood cell dose that satisfies all of the following conditions for umbilical cord blood (UCB) dose reduction , i.e.:
|
up to 12 months
|
Correlation between neutrophil and platelet engraftment and CD34+ and CD34+CD45RA- dose
Time Frame: 42 days post transplant
|
Time to neutrophil and platelet engraftment will be correlated to the CD34+ and the CD34+CD45RA- dose (which includes all human hematopoietic stem cells (HSCs): long term and short term repopulating cells) contained in the expanded graft.
Expansion and cultures might change the characteristics and behaviour of CD34+ cells, hence the need to look at the correlation between primitive CD34+CD45RA- subpopulation and engraftment.
|
42 days post transplant
|
Incidence of primary and late graft failure
Time Frame: 42 days post transplant
|
The patient will be declared as having developed primary graft failure if:
Secondary or late graft failure when: • ANC drops below 0.5 x 109/L for 14 consecutive days unresponsive to growth colony stimulating factor (G-CSF) witout identifiable cause (medication, viral infection, vitamin deficience or other) |
42 days post transplant
|
Incidence of backup cord infusion and graft dominance
Time Frame: 7, 14, 21, 28, 56, 100 days and at 6 and 12 months
|
This evaluation will be performed in lymphoid and myeloid cells to determine the expanded cord's role in short and long term engraftment in patients. Cell sorting to examine chimerism of different cell subsets will be performed with complex of differentiation (CD) such as CD3, CD33, CD56, CD14 and CD19 to determine the proportions in which donor's immune cells are represented in the graft recipient. Donor cell engraftment is defined as donor cell (lymphoid or myeloid) chimerism ≥ 5% by day +42 post transplant. Full donor chimerism is defined as ≥ 95% donor myeloid and lymphoid chimerism. |
7, 14, 21, 28, 56, 100 days and at 6 and 12 months
|
Incidence of acute and chronic GVHD
Time Frame: through study completion (3 years follow-up)
|
The incidence of acute and chronic GVHD will be evaluated throughout the study using NIH criteria. Acute GVHD will be defined as classic acute (time of onset of symptoms ≤ 100 days) or persistent, recurrent, or late onset acute GVHD (time of onset of symptoms > 100 days) as defined by the NIH. Patients will be assessed for the presence of chronic GVHD at each medical evaluation. Data will be collected directly from providers and chart review according to the recommendations of the NIH Consensus Conference. |
through study completion (3 years follow-up)
|
Incidence of severe infectious complications
Time Frame: through study completion (3 years follow-up)
|
any grade 3 infection will be tabulated as well as any of the following infections requiring systemic therapy will be captured: invasive candidiasis, aspergillus, other invasive fungi, cytomegalovirus (CMV), adenovirus, Epstein-Barr virus (EBV), Human herpes virus (HHV-6), herpes simplex (HSV), varicella-zoster virus (VZV), Pneumocystis carinii pneumonitis (PCP), toxoplasmosis and mycobacterium.
Severity of infections will be graded according to the Technical Manual of Procedure of the Blood and Marrow Transplant Clinical Trials Network.
|
through study completion (3 years follow-up)
|
T cell evaluation (Cluster of differentiation (CD) 4+ and CD8+)
Time Frame: 3, 6, 12, and 18 months
|
Multiparametric flow cytometry to quantify the proportion of naïve (CD45RA+/CD27+) and memory (CD45RA-/CD27+) cells.
|
3, 6, 12, and 18 months
|
B cell evaluation
Time Frame: 3, 6, 12, and 18 months
|
The outcome (success or failure) in B cell recovery will be evaluated by flow cytometry, immunoglobulin measurements and PCR for donor cell chimerism.
|
3, 6, 12, and 18 months
|
Natural Killer (NK) cell evaluation
Time Frame: 3, 6, 12, and 18 months
|
The outcome (success or failure) in NK cell recovery will be evaluated by flow cytometry and PCR for donor cell chimerism.
|
3, 6, 12, and 18 months
|
Transplant related mortality (TRM)
Time Frame: 100 days and 1,2, 3 years post transplant
|
Incidence of TRM will be monitored throughout the study and in particular at 100 days, 1, 2, and 3 years post transplantation.
If it should exceed 30% at day 100, stopping rules may apply that could prematurely terminate the trial.
|
100 days and 1,2, 3 years post transplant
|
progression free survival
Time Frame: 100 days an 1,2, 3 years post transplant
|
Progression free survival (PFS) will be monitored throughout the study and in particular at 1, 2, and 3 years post-transplant. PFS will be measured from time of transplant until progression, death or last follow-up. PFS: an event is defined as relapse/progression or death. |
100 days an 1,2, 3 years post transplant
|
Overall survival
Time Frame: 100 days an 1,2, 3 years post transplant
|
Overall survival (OS) will be monitored throughout the study and in particular at 1, 2, and 3 years post-transplant. OS will be measured from time of transplant until progression, death or last follow-up. OS: an event is defined as death. |
100 days an 1,2, 3 years post transplant
|
Incidence of engraftment syndrome requiring therapy
Time Frame: 24 hours post transplant and during follow-up (3 years)
|
Patients will be monitored for the occurrence of engraftment and preengraftment syndromes (ES and PES) as well as the necessity for treatment.
Diagnostic criteria for ES are noninfectious fever plus any of the following: skin rash, pulmonary infiltrates, hepatic dysfunction, or diarrhea.
|
24 hours post transplant and during follow-up (3 years)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sandra Cohen, MD, Maisonneuve-Rosemont Hospital
Publications and helpful links
General Publications
- Dumont-Lagace M, Li Q, Tanguay M, Chagraoui J, Kientega T, Cardin GB, Brasey A, Trofimov A, Carli C, Ahmad I, Bambace NM, Bernard L, Kiss TL, Roy J, Roy DC, Lemieux S, Perreault C, Rodier F, Dufresne SF, Busque L, Lachance S, Sauvageau G, Cohen S, Delisle JS. UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections. Transplant Cell Ther. 2021 Jan;27(1):76.e1-76.e9. doi: 10.1016/j.bbmt.2020.09.031. Epub 2020 Oct 3.
- Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, Roy DC, Barabe F, Ahmad I, Bambace N, Bernard L, Kiss T, Bouchard P, Caudrelier P, Landais S, Larochelle F, Chagraoui J, Lehnertz B, Corneau S, Tomellini E, van Kampen JJA, Cornelissen JJ, Dumont-Lagace M, Tanguay M, Li Q, Lemieux S, Zandstra PW, Sauvageau G. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2020 Feb;7(2):e134-e145. doi: 10.1016/S2352-3026(19)30202-9. Epub 2019 Nov 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UM0128171
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
CRISPR Therapeutics AGEnrolling by invitationHematologic Malignancy | Solid MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
Clinical Trials on Transplantation of cord blood expanded with UM171
-
ExCellThera inc.California Institute for Regenerative Medicine (CIRM)WithdrawnSickle Cell Disease | Umbilical Cord Blood | Hematopoietic Cell ProliferationUnited States
-
ExCellThera inc.Fred Hutchinson Cancer CenterActive, not recruitingHigh Risk Hematological Malignancy | Cord Blood TransplantUnited States, Netherlands
-
Ciusss de L'Est de l'Île de MontréalExCellThera inc.; Centre C3iActive, not recruitingMultiple MyelomaCanada
-
Novartis PharmaceuticalsWithdrawnInherited Metabolic Disorders IMD
-
Center for International Blood and Marrow Transplant...CompletedHematologic Malignancies | Cord Blood Stem Cell TransplantationUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedAcute Myeloid LeukemiaFrance
-
Universitair Ziekenhuis BrusselCompletedAllogeneic Stem Cell TransplantationBelgium
-
Mesoblast, Ltd.CompletedNon-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Hodgkin's DiseaseUnited States
-
Ciusss de L'Est de l'Île de MontréalExCellThera inc.; Stem Cell NetworkActive, not recruitingCord Blood Transplant | High Risk Hematologic MalignancyCanada
-
Assistance Publique - Hôpitaux de ParisCompletedPatients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch DonorFrance